Luca Maroni

Dr. Luca Maroni

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2016 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Open access
PDF file
Jesús BañalesJesús Bañales
Jesús Bañales
VCVincenzo Cardinale
Vincenzo Cardinale
GCGuido Carpino
Guido Carpino
MMMarco Marzioni
Marco Marzioni
JAJesper B Andersen
Jesper B Andersen
DADomenico Alvaro
Domenico Alvaro
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies with features of biliary tract differentiation. CCA is the second most common primary liver tumour and the incidence is increasing worldwide. CCA has high mortality owing to its aggressiveness, late diagnosis and refractory nature. In May 2015, the “European Network for the Study of Cholangiocarcinoma” (ENS-CCA: www.enscca.org or www.cholangiocarcinoma.eu) was created to promote and boost international research collaboration on the study of CCA at basic, translational and clinical level. In this Consensus Statement, we aim to provide valuable information on classifications, pathological features, risk factors, cells of origin, genetic and epigenetic modifications and current therapies available for this cancer. Moreover, future directions on basic and clinical investigations and plans for the ENS-CCA are highlighted.

1 September 2018 in The Lancet Gastroenterology & Hepatology
Verified
Journal Article
Open access
Marco CarboneMarco Carbone
Marco Carbone
ANAlessandra Nardi
Alessandra Nardi
SFSteve Flack
Steve Flack
GCGuido Carpino
Guido Carpino
NVNikoletta Varvaropoulou
Nikoletta Varvaropoulou
APAntonino Picciotto
Antonino Picciotto
Treatment guidelines recommend a stepwise approach to primary biliary cholangitis: all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those with an inadequate biochemical response after 12 months are subsequently considered for second-line therapies. However, as a result, patients at the highest risk can wait the longest for effective treatment. We determined whether UDCA response can be accurately predicted using pretreatment clinical parameters. We did logistic regression analysis of pretreatment variables in a discovery cohort of patients in the UK with primary biliary cholangitis to derive the best-fitting model of UDCA response, defined as alkaline phosphatase less than 1·67 times the upper limit of normal (ULN), measured after 12 months of treatment with UDCA. We validated the model in an external cohort of patients with primary biliary cholangitis and treated with UDCA in Italy. Additionally, we assessed correlations between model predictions and key histological features, such as biliary injury and fibrosis, on liver biopsy samples. 2703 participants diagnosed with primary biliary cholangitis between Jan 1, 1998, and May 31, 2015, were included in the UK-PBC cohort for derivation of the model. The following pretreatment parameters were associated with lower probability of UDCA response: higher alkaline phosphatase concentration (p<0·0001), higher total bilirubin concentration (p=0·0003), lower aminotransferase concentration (p=0·0012), younger age (p<0·0001), longer interval from diagnosis to the start of UDCA treatment (treatment time lag, p<0·0001), and worsening of alkaline phosphatase concentration from diagnosis (p<0·0001). Based on these variables, we derived a predictive score of UDCA response. In the external validation cohort, 460 patients diagnosed with primary biliary cholangitis were treated with UDCA, with follow-up data until May 31, 2016. In this validation cohort, the area under the receiver operating characteristic curve for the score was 0·83 (95% CI 0·79-0·87). In 20 liver biopsy samples from patients with primary biliary cholangitis, the UDCA response score was associated with ductular reaction (r=-0·556, p=0·0130) and intermediate hepatocytes (probability of response was 0·90 if intermediate hepatocytes were absent vs 0·51 if present). We have derived and externally validated a model based on pretreatment variables that accurately predicts UDCA response. Association with histological features provides face validity. This model provides a basis to explore alternative approaches to treatment stratification in patients with primary biliary cholangitis. UK Medical Research Council and University of Milan-Bicocca.

1 July 2015 in Cellular and Molecular Gastroenterology and Hepatology
Verified
Journal Article
Open access
LMLuca Maroni
Luca Maroni
BHBai Haibo
Bai Haibo
DRDebolina Ray
Debolina Ray
TZTianhao Zhou
Tianhao Zhou
YWYing Wan
Ying Wan
GAGianfranco Alpini
Gianfranco Alpini
Cholangiocytes are the epithelial cells that line the bile ducts. Along the biliary tree, two different kinds of cholangiocytes exist: small and large cholangiocytes. Each type has important differences in their biological role in physiologic and pathologic conditions. In response to injury, cholangiocytes become reactive and acquire a neuroendocrine-like phenotype with the secretion of a number of peptides. These molecules act in an autocrine/paracrine fashion to modulate cholangiocyte biology and determine the evolution of biliary damage. The failure of such mechanisms is believed to influence the progression of cholangiopathies, a group of diseases that selectively target biliary cells. Therefore, the understanding of mechanisms regulating cholangiocyte response to injury is expected to foster the development of new therapeutic options to treat biliary diseases. In this review, we discuss the most recent findings in the mechanisms driving cholangiocyte adaptation to damage, with particular emphasis on molecular pathways that are susceptible of therapeutic intervention. Morphogenic pathways (Hippo, Notch, Hedgehog), which have been recently shown to regulate biliary ontogenesis and response to injury, are also reviewed as well as the results of ongoing clinical trials evaluating new drugs for the treatment of cholangiopathies.

1 April 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
CPClaudio Pinto
Claudio Pinto
DGDebora Maria Giordano
Debora Maria Giordano
LMLuca Maroni
Luca Maroni
MMMarco Marzioni
Marco Marzioni

15 May 2014 in Clinical Reviews in Allergy & Immunology
Verified
Journal Article
Closed access
PDF file
LMLuca Maroni
Luca Maroni
SGStan van de Graf
Stan van de Graf
SHSimon Hohenester
Simon Hohenester
RERonald P. J. Oude Elferink
Ronald P. J. Oude Elferink
UBUlrich Beuers
Ulrich Beuers

1 February 2017 in The American Journal of Pathology
Verified
Journal Article
Closed access
LMLuca Maroni
Luca Maroni
LALaura Agostinelli
Laura Agostinelli
SSStefania Saccomanno
Stefania Saccomanno
CPClaudio Pinto
Claudio Pinto
DGDebora M. Giordano
Debora M. Giordano
MMMarco Marzioni
Marco Marzioni